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Alteration of the surface glycosylation pattern on malignant cells potentially affects tumor immunity by 
directly influencing interactions with glycan-binding proteins (lectins) on the surface of immunomodulatory 
cells. The sialic acid–binding Ig-like lectins Siglec-7 and -9 are MHC class I–independent inhibitory receptors 
on human NK cells that recognize sialic acid–containing carbohydrates. Here, we found that the presence of 
Siglec-9 defined a subset of cytotoxic NK cells with a mature phenotype and enhanced chemotactic potential. 
Interestingly, this Siglec-9+ NK cell population was reduced in the peripheral blood of cancer patients. Broad 
analysis of primary tumor samples revealed that ligands of Siglec-7 and -9 were expressed on human cancer 
cells of different histological types. Expression of Siglec-7 and -9 ligands was associated with susceptibility 
of NK cell–sensitive tumor cells and, unexpectedly, of presumably NK cell–resistant tumor cells to NK cell–
mediated cytotoxicity. Together, these observations have direct implications for NK cell–based therapies and 
highlight the requirement to consider both MHC class I haplotype and tumor-specific glycosylation.
Introduction
Upon malignant transformation, sialic acid–containing carbohy-
drates (sialoglycans) can be aberrantly expressed by tumor cells as 
a result of genetic or epigenetic dysregulation of glycan synthe-
sis pathways (e.g., glycosyltransferases) (1–4). Distinctly glycosyl-
ated tumor antigens on the cell surface or on secreted molecules 
(e.g., mucins) are diagnostically exploited as tumor markers 
(e.g., CA125, MUC1, CEA, and CA19-9). Sialoglycans influence 
many critical steps in tumor biology, including immunoediting, 
tumor growth and proliferation, invasion, metastasis, and angio-
genesis; in some instances, their presence has been correlated with 
poor patient survival (1, 2, 5–8).
NK cells act as first line of defense in tumor immunosurveillance 
(9). Distinct sialoglycan determinants are recognized as ligands 
to sialic acid–binding Ig-like lectin–7 (Siglec-7; also known as 
p75/AIRM1) and Siglec-9 receptors on human NK cells (10), which 
— similar to the classical inhibitory receptors CD94/NKG2A, killer 
Ig–like receptors (KIRs), and Ig-like transcripts (ILTs) — contain 1 
or more immunoreceptor tyrosine-based inhibition motifs (ITIMs) 
in their cytoplasmic tail (11, 12). Recognition of MHC class I by 
inhibitory NK cell receptors provided the molecular basis of the 
“missing-self” hypothesis to explain the rejection of stressed, trans-
formed, or infected cells that lack or downregulate cognate MHC 
class I molecules, and the associated capacity of NK cells to dis-
criminate between healthy self and target cells (13, 14). While in 
recent years, significant novel insights have accumulated on the 
role of MHC class I–specific inhibitory receptors in NK cell biology 
and tumor immunology (most notably in allogeneic hematopoi-
etic stem cell transplantation for hematologic malignancies; ref. 9), 
comparably less is known about the role of MHC class I–indepen-
dent ITIM-bearing receptors. Protection of tumor cells from innate 
immune attack can result from aberrant expression of sialoglycan 
ligands that engage the MHC class I–independent Siglec-7 and -9 
receptors to govern NK cell inhibition.
NK cell subsets of humans consist of CD56dim NK cells 
(CD56dimCD16+KIR+), which represent about 90% of peripheral 
blood and spleen NK cells, express perforin and granzymes, and 
are the major cytotoxic subset (15, 16), and CD56bright NK cells 
(CD56brightCD16dim/–KIR–), which constitute the majority of NK 
cells in lymph nodes and tonsils and, upon activation, primarily 
respond with cytokine production (17). Whereas Siglec-7 is known 
as a pan–NK cell marker (18, 19), Siglec-9 was recently reported to 
be selectively expressed in a subset of CD56dim NK cells (20).
Siglecs comprise a lectin family of surface receptors that bind 
to sialoglycans and are predominantly expressed on cells of the 
hematopoietic system in a manner dependent on cell type and dif-
ferentiation (21–24). Whereas sialic acid is ubiquitously expressed, 
typically at the terminal position of glycoproteins and -lipids, only 
very specific, distinct sialoglycan structures are recognized by indi-
vidual Siglec receptors, depending on identity and linkage to sub-
terminal carbohydrate moieties (22, 24). Knowledge about Siglec 
expression and function on NK cell subsets is still limited in terms 
of NK cell differentiation and maturation, and the role of Siglec 
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ligand-receptor interactions in disease remains to be explored. 
Whether Siglec-7 and -9 ligands in human cancer are expressed on 
malignant or healthy cells is a subject of controversy (3, 25–28), as 
is the related question as to whether absence of inhibitory Siglec-
ligand interactions promotes or inhibits tumor progression, either 
by uncoupled immune stimulation or by inhibition of immune 
defense (10, 25–27). Here, we found that Siglec-7 and -9 ligands were 
significantly overexpressed on a broad range of human malignant 
cells of different histological types and that surface Siglec-7 and -9 
ligand expression determined cytotoxicity of human primary NK 
cells against both NK cell–susceptible and –resistant tumor cells. 
Given that Siglec-7 and -9, in analogy to KIRs, exist in humans but 
not in rodents (22), we performed in vivo experiments in mice with a 
reconstituted human NK cell compartment. Further in-depth analy-
sis revealed that CD56dimSiglec-9+ NK cells exhibited a more mature 
phenotype with distinct functional properties, such as enhanced 
chemotactic potential, and that the frequency of this subset was sig-
nificantly reduced in the peripheral blood of cancer patients.
Results
Siglec-7 and -9 ligands are widely expressed on tumor cells of different his-
tological origins. To determine the extent to which tumors express 
Siglec-7 and -9 ligands, we directly probed tumor cells and tissue 
sections using recombinant chimeras of Siglec molecules fused to 
human IgG1 Fc domains, as this strategy takes into account the 
spatial and complex cellular organization of sialoglycan ligands 
(29). High expression of Siglec-7 ligands was detected by flow 
cytometry on numerous cell lines, including HeLa cells and various 
leukemic (e.g., K562) and melanoma (e.g., A375) cells (Figure 1A). 
Staining for Siglec-9 ligands revealed an even broader expression 
profile, as high fluorescence signal intensities were detectable 
in the majority of tested cell lines, notably in those originating 
from hematologic malignancies and melanoma. In contrast to 
their malignant counterparts, Siglec-7 and -9 ligand expres-
sion in human PBMCs or primary melanocytes was low or 
undetectable (Figure 1A). Staining by a recombinant CD33-Fc 
fusion molecule was consistently negative in the tested cell lines 
(data not shown and Supplemental Figure 1A; supplemental mate-
rial available online with this article; doi:10.1172/JCI65899DS1), 
thus excluding binding mediated by nonspecific Fc (IgG1). Con-
focal microscopic analysis of A375 melanoma cells revealed an 
intense cell surface–associated expression pattern, with only sparse 
intracellular staining for Siglec-7 and -9 ligands (Figure 1B). Bind-
ing of Siglec-7–Fc and Siglec-9–Fc fusion proteins was abrogated 
after enzymatic digestion of sialoglycans by neuraminidase (also 
known as sialidase) (30), thus confirming the sialic acid depen-
dency of the staining. To confirm expression of Siglec-7 and -9 
ligands in human malignancies, leukemic cells from patients 
with acute myeloid leukemia (AML) and chronic lymphocytic leu-
kemia (CLL) were analyzed for Siglec-7 and -9 ligand expression 
by flow cytometry. Leukemic cells from all AML (n = 3) and CLL 
(n = 3) patients consistently stained highly double-positive for 
both Siglec-7 and -9 ligand expression (Figure 1C and Supplemen-
tal Figure 1B). To further confirm in situ expression of Siglec-7 and 
-9 ligands, immunohistochemistry on paraffin-embedded sections 
from human primary tumor specimens from melanoma, basal cell 
carcinoma (BCC), squamous cell carcinoma (SCC), and cutane-
ous T cell lymphoma (CTCL) patients was performed (n = 3 each; 
Figure 1D). Coexpression of Siglec-7 and -9 ligands was found in 
specimens from 5 of 6 melanoma patients and was restricted to 
malignant cells. In contrast, no Siglec-7 or -9 ligand expression was 
found in the analyzed BCC, SCC, and CTCL specimens. Next, the 
melanoma cell–restricted expression of Siglec-7 and -9 ligands was 
further confirmed by confocal microscopy analysis. Melan-A–pos-
itive malignant melanoma cells displayed expression of Siglec-7 
and -9 ligands, whereas staining of normal tissue was not detect-
ed in epidermal or dermal layers, nor in tumor-free skin sections 
(Figure 1E, Supplemental Figure 1, C–E, and data not shown), 
which indicated that the expression of Siglec-7 and -9 ligands in 
skin is confined to malignant cells.
Siglec-7 and -9 ligand expression protects tumor cells from NK cell 
responses. Next, we assessed the requirement of sialoglycan ligands 
to protect from NK cell lysis in cell lines with high (e.g., K562 
and HeLa) or absent (e.g., 721.221) expression of Siglec-7 and 
-9 surface ligands. Desialylation by neuraminidase significantly 
enhanced cytolysis of NK cell–susceptible K562 cells by human 
peripheral blood NK cells in vitro, as measured in a 51Cr release 
assay (Figure 2, A and B). Similar results were obtained with HeLa 
cells (Figure 2, A and C), which indicated that desialylation even 
enhances the susceptibility of NK cell–resistant cells. In contrast, 
neuraminidase treatment had no effect on 721.221 cells (Figure 2A 
and Supplemental Figure 2). Consistent with these results, signifi-
cant upregulation of the degranulation marker CD107a was found 
on NK cells exposed to desialylated K562 or HeLa target cells, but 
not to Siglec-7 and -9 ligand–negative 721.221 cells (Figure 2D). 
Intracellular synthesis of the cytokines IFN-γ and TNF-α and of 
the chemokine macrophage inflammatory protein–1β (MIP-1β) 
was increased in NK cells exposed to neuraminidase-treated K562 
cells (Figure 2E and Supplemental Figure 3).
The sialome, defined as “total complement of sialic acid types 
and linkages and their modes of presentation on a particular 
organelle, cell, tissue, organ, or organism” (31), varies substantially 
among different species (22), and no orthologs or unambiguous 
functional paralogs for Siglec-7 or -9 exist in rodents (21). There-
fore, we chose humanized NOD-SCID-γc–/– (huNSG) mice with a 
reconstituted human NK cell compartment (32) to test the tumor-
protective role of sialoglycans in vivo. Circulating NK cells of 
huNSG mice expressed high levels of Siglec-7 (Supplemental Fig-
ure 4). Peritoneal injection of tumor cells in huNSG mice resulted 
in recruitment of human NK cells (human NKp46+, murine CD45–) 
within hours (data not shown). Before injection, neuraminidase-
treated K562 or HeLa cells were labeled with lower CFSE concen-
trations compared with untreated controls, which allowed for 
discrimination between desialylated (low signal intensity) and 
nondesialylated (high signal intensity) tumor cells. Siglec-7 and 
-9 ligands on K562 cells were not reexpressed within 24 hours of 
neuraminidase treatment (Supplemental Figure 5). Desialylated 
and untreated K562 or HeLa cells were simultaneously injected at 
a 1:1 ratio into the peritoneal cavity of poly I:C–pretreated huNSG 
mice (32). Flow cytometric analysis of the peritoneal lavage as early 
as 12 hours after injection revealed a decrease in the total numbers 
of K562 and HeLa cells (29.8% and 41.8% decreases, respectively). 
The loss of cells was much more pronounced among desialylated 
tumor cells, as concomitantly a higher percentage of untreated, 
fully glycosylated tumor cells was recovered (Figure 2F).
To further substantiate a tumor-protective role of Siglec-7 and -9 
ligands, we generated Fab fragments from mAbs against Siglec-7 
(clone Z176) and Siglec-9 (clone E10-286) to specifically block ligand-
receptor interactions. Anti–Siglec-7 and anti–Siglec-9 Fabs at 5 μg/ml 
led to substantially enhanced NK cell cytotoxicity against K562 and 
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Figure 1
Human tumor cells express variable, but significant, levels of Siglec-7 and -9 ligands. (A–C and E) Immunofluorescence binding studies by 
flow cytometry (A and C) or immunofluorescence confocal microscopy (B and E) using recombinant Siglec-Fc (human IgG1) fusion proteins 
coupled to secondary PE-conjugated (Fab′)2 goat anti-human Fc antibody. (A) Broad analysis of ligand expression to Siglec-7 and -9 on different 
tumor cell lines, as well as on primary melanocytes (n = 2) and PBMCs (n = 9) from healthy donors for comparison. Values are expressed as 
geometric mean fluorescence intensity (GMFI) ratio of specific staining compared with secondary antibody only. (B) Expression of Siglec-7 and 
-9 ligands on A375 melanoma cells was localized to the cell surface. Staining was lost upon neuraminidase treatment (sialic acid dependency). 
Original magnification, ×630. (C) Expression levels of Siglec-7 and -9 ligands on CLL and AML cells, as revealed by flow cytometric analysis. 
Histograms are representative of 3 CLL and 3 AML patients. (D) Lectin immunohistochemistry for Siglec-7 and -9 ligand expression in paraffin-
embedded tissues representative of melanoma, BCC, SCC, and CTCL sections. Scale bars: 100 μm (melanoma, BCC, and SCC); 50 μm (CTCL). 
(E) Paraffin-embedded primary tissue biopsy sections of malignant melanoma lesions in epidermal skin layers, costained for the melanoma mark-
er Melan-A and Siglec-7 or Siglec-9 ligands. Scale bars: 50 μm. Data are representative of at least 2 (B), 3 (D), or 5 (E) independent experiments.
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HeLa cells, but not against 721.221 cells (Figure 3A), the latter of 
which expressed neither Siglec-7 nor -9 ligands (see above). The per-
missive effect of anti–Siglec-7 and anti–Siglec-9 Fabs was observable 
at different effector/target (E/T) ratios (Figure 3, A–C), but blocking 
Siglec-9 was slightly less efficient compared with blocking Siglec-7 
(Figure 3A), consistent with the lower frequency and reduced kill-
ing capacity of CD56dimSiglec-9+ NK cells. The combination of Fab 
fragments of Siglec-7 and -9 had no additive effect in potentiating 
NK cell cytotoxicity (Supplemental Figure 6), likely because both of 
these structurally related receptors target similar intracellular signal-
ling pathways. We also used intact mAbs to exploit their agonistic 
action, which has been demonstrated in previous studies (18, 33). NK 
cell cytotoxicity was inhibited by ligation of Siglec-7 and -9 by intact 
anti–Siglec-7 and anti–Siglec-9 mAbs (Z176 and E10-286, respective-
ly), but not by the null clone 191240 against Siglec-9 (Figure 3C and 
Supplemental Figure 7A). Anti–Siglec-9 did not affect the cytotoxic 
activity of sorted CD56dimSiglec-9– NK cells (Supplemental Figure 
7B). Anti–Siglec-7 and, to a lesser extent, anti–Siglec-9 mAbs inhib-
ited CD107a upregulation and IFN-γ secretion of NK cells, but had 
no effect on their survival or proliferation (Figure 3, D and E, and 
Supplemental Figure 7, C and D).
Siglec-9 defines a subset of mature cytotoxic CD56dim NK cells with 
enhanced chemotactic potential. Next, we set out to phenotypically 
and functionally characterize human primary NK cells expressing 
Siglec-7 and -9, and eventually to identify other Siglecs involved in 
modulating the effector function of NK cells. Human peripheral 
blood NK cells were screened by flow cytometry, which demon-
strated the exclusive presence of Siglec-7 and -9 on NK cell sur-
faces (Supplemental Figure 8A). This observation was confirmed 
after neuraminidase treatment (Supplemental Figure 8A), to 
remove potentially “masking” sialoglycans bound in cis on the 
same cell membrane (21). Whereas Siglec-7 was ubiquitously 
distributed in the NK cell compartment, Siglec-9 was absent on 
CD56bright NK cells, but selectively expressed on about 40%–50% 
of CD56dim NK cells, 10%–20% of which was masked, as revealed 
by neuraminidase treatment (Supplemental Figure 8B). Surface 
expression of Siglec-9 on total NK cells or fluorescence-activated 
cell sorted CD56dimSiglec-9+ NK cell subsets was not influenced 
by exposure to the cytokines IL-2, IL-8, IL-12, IL-15, IL-18, or 
IL-21, alone or in combination, nor did these cytokines induce 
Siglec-9 expression in Siglec-9– subsets (Supplemental Figure 8, 
C and D, and data not shown).
Figure 2
Desialylation of target cells that express ligands of Siglec-7 and -9 enhances NK cell cytotoxicity and cytokine secretion. (A–C) Cytotoxicity of 
isolated peripheral blood NK cells from healthy donors against K562 (A and B), HeLa (A and C), and 721.221 (A) cell lines, assessed in a 51Cr 
release assay, without or with neuraminidase treatment of target cells. Cytotoxicity was evaluated at a 10:1 E/T ratio (A) or as indicated (B and 
C). (D) Flow cytometric CD107a measurement on NK cells after coculture with desialylated or untreated K562, HeLa, or 721.221 cells at a 1:1 E/T 
ratio. (E) Intracellular cytokine measurement in NK cells in the presence of K562 cells with or without neuraminidase treatment (10:1 E/T ratio). 
(F) Flow cytometry of CFSE-labeled HeLa and K562 cells, prior to intraperitoneal injection (Pre-transfer) and after recovery 12 hours later in 
individual poly I:C–preactivated huNSG mice (no. 1–3 for HeLa; no. 1–5 for K562). Percentage of CFSEhi (wild-type K562 and HeLa) and CFSElo 
(desialylated K562 and HeLa; red boxes) cells is indicated. **P < 0.005, ***P < 0.001, Student’s t test. Data are representative of at least 5 (A–C), 
7 (D), 4 (E), and 2 (F) independent experiments.
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Upon release from the bone marrow, human immature 
CD56bright NK cells may undergo differentiation to CD56dim 
NK cells in the periphery, a process that is paralleled by the 
acquisition (e.g., increasing number of KIRs, CD57) or loss 
(e.g., NKG2A, CD27) of distinct and characteristic molecules 
(34, 35). CD27, a molecule expressed by naive cells, was not 
detectable in the CD56dimSiglec-9+ subset; inversely, markers 
that typically define mature cells, like CD57 and KLRG1, were 
significantly upregulated in CD56dimSiglec-9+ cells compared 
with the CD56dimSiglec-9– subset (Figure 4A). Expression of the 
activation marker CD69 was higher on CD56dimSiglec-9+ cells, 
whereas no difference in CD25 expression was observed (data 
not shown).
To assess the replicative history of these NK cell subsets, we 
measured telomere length in CD56bright, CD56dimSiglec-9+, and 
CD56dimSiglec-9– NK cells isolated from the peripheral blood of 
3 healthy donors using automated multicolor f low-FISH 
(see Methods). Consistent with being less mature, CD56bright cells 
showed a trend for longer telomeres than CD56dim NK cells (mean, 
5.00 ± 0.58 kb versus 4.56 ± 0.41 kb; P = 0.220; Figure 4B). In con-
trast, CD56dimSiglec-9+ and CD56dimSiglec-9– NK cells had similar 
mean telomere lengths (4.56 ± 0.51 and 4.55 ± 0.39 kb, respectively).
Next, we used flow cytometry to compare the expression of 
Siglec-7 and -9 on NK cells in human cord blood and adult periph-
eral blood. Even without unmasking by neuraminidase treatment, 
cord blood CD56bright NK cells stained consistently Siglec-7+, 
whereas adult peripheral blood cells exhibited broader staining 
variability (Figure 4, C and D). Expression levels of Siglec-7 and -9 
were higher on cord blood CD56dim NK cells compared with their 
adult counterparts, and 40% of untreated and 60% of neuramini-
dase-treated cells were Siglec-9+. Upon neuraminidase treatment, 
about 10% of CD56bright NK cells from cord blood were Siglec-9+. 
Together, these results suggested that acquisition of Siglec-9 is an 
early event upon differentiation from CD56bright to CD56dim NK 
cells, while its expression is either transient or stabilized in a subset 
of cells reaching full maturation.
CD56dimSiglec-9+ NK cells exhibited a significantly reduced 
cytotoxic capacity against K562 target cells compared with 
CD56dimSiglec-9– NK cells (Figure 5A), which we eventually attributed 
to the elevated expression of inhibitory receptors (e.g., KIRs and ILT2) 
found on these cells (Figure 5, B and C). In contrast, expression 
of the activating receptor NKG2D and the natural cytotoxicity 
receptors (NCRs) NKp46 and NKp30 was similar between the 
CD56dimSiglec-9+ and CD56dimSiglec-9– NK cell subsets (Supplemen-
Figure 3
NK cell responses are attenuated after engagement of Siglec-7 and -9 by ligands on tumor cells or targeting with agonistic mAbs. (A and 
B) Cytotoxicity of isolated peripheral blood NK cells from healthy donors against K562, HeLa, and 721.221 cells in the presence of blocking 
anti–Siglec-7 (clone Z176) and anti–Siglec-9 (clone E10-286) Fab fragments at 10:1 E/T ratios (A) or as indicated (B), as assessed in a 51Cr-
release assay. (C) Cytotoxicity of isolated peripheral blood NK cells from healthy donors against K562 cells in the presence or absence of intact 
anti–Siglec-7 or anti–Siglec-9 agonistic mAbs at the indicated E/T ratios, as assessed in a 51Cr release assay. (D) Flow cytometric CD107a 
measurement on NK cells, in the presence or absence of intact anti–Siglec-7 or anti–Siglec-9 mAbs. (E) Inhibition of IFN-γ secretion after activa-
tion of NK cells with IL-12 and IL-18, in the presence or absence of the indicated intact mAbs. *P < 0.05, **P < 0.005, Student’s t test. Data are 
representative of at least 5 (A and B), 10 (C), or 6 (D and E) independent experiments.
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tal Figure 9). CD56dimSiglec-9+ NK cells exhibited higher expression 
of the chemokine receptors CXCR1 and CX3CR1, while the receptors 
CXCR3, CCR5, and CCR7 were virtually absent (Figure 5, E and F). 
Since the most striking difference between CD56dimSiglec-9+ and 
CD56dimSiglec-9– NK cells was found for CXCR1, we compared their 
relative chemotactic capacity toward a gradient of the CXCR1 ligand 
IL-8, a known chemoattractant for NK cells (36, 37). Highly pure 
fluorescence-activated cell sorted CD56dimSiglec-9+ and CD56dimSi-
glec-9– NK cells were stimulated to migrate to a gradient of 1 nM 
recombinant human IL-8 (rhIL-8). Concordantly with the higher 
CXCR1 expression, CD56dimSiglec-9+ NK cells exhibited a signifi-
cantly higher propensity for chemotaxis toward IL-8 (Figure 5D).
CD56dimSiglec-9+ NK cells are reduced in peripheral blood of cancer 
patients. Given the peculiar characteristics of the CD56dimSiglec-9+ 
NK cell subset and the well-established role of NK cells in anti-
tumor immune responses (9), we next determined whether NK 
cells isolated from peripheral blood from cancer patients dis-
play altered occurrence of NK cell subsets or expression levels of 
Siglec-7 and -9 receptors. Compared with healthy donors (n = 22), 
absolute numbers of total NK cells among PBLs were similar in 
patients with colon adenocarcinoma (CoACA; n = 10) or malig-
nant melanoma (n = 11) (Supplemental Figure 10A). Furthermore, 
no difference in terms of the cytolytic capacity of NK cells was 
observed between NK cells from melanoma patients and healthy 
donors (Supplemental Figure 10B). For flow cytometric analysis of 
Siglec-7 and -9, NK cells were analyzed with or without neuramini-
dase pretreatment to exclude masking effects by bound sialogly-
can ligands. Siglec-7 was expressed at similar levels on peripheral 
blood NK cells of cancer patients and healthy donors (Supplemen-
tal Figure 10C). Interestingly, both positivity and expression levels 
of Siglec-9 among peripheral blood CD56dim NK cells were signifi-
cantly reduced in the malignant melanoma and CoACA patients 
compared with healthy donor controls (Figure 6, A and B). 
Neuraminidase treatment enhanced the staining, which suggests 
that Siglec-9 receptors are partially masked by bound sialogly-
cans. However, Siglec-9 staining after unmasking by enzymatic 
treatment remained lower in NK cells of cancer patients, which 
confirmed that the expression of this surface receptor is reduced 
in cancer. The reduced occurrence of CD56dimSiglec-9+ NK cells in 
peripheral blood of cancer patients might eventually be associated 
with the enhanced chemotactic properties of this subset (migra-
tion), but is likely attributable to other, yet-unknown factors, 
including cell-specific characteristics.
Discussion
Altered surface glycosylation with overexpression of sialoglycans 
that engage inhibitory Siglec receptors on NK cells may provide a 
general mechanism to shield tumor cells from innate immunity. 
By this strategy, tumor cells might counter NK cell activation, after 
loss of MHC class I expression (missing-self) and disengagement 
Figure 4
Siglec-9 defines a subset of NK cells with a more mature phenotype, yet similar telomere length, present in adult and cord blood. (A) Flow cytom-
etry for surface expression of adhesion and activation markers. Shown are frequency and GMFI ratio of specific staining to isotype-matched 
control. (B) Telomere length analysis of different NK cell subsets from 3 healthy donors (HD). 50th percentile is shown as lines within boxes and 
numerals; upper and lower margins of the boxes denote 25th and 75th percentile; whiskers denote 5th and 95th percentile. (C and D) Siglec-7 
and -9 expression among NK cell subsets in adult peripheral blood (PB; n = 14 [Siglec-7], 27 [Siglec-9]) and cord blood (n = 9). *P < 0.05, 
**P < 0.005, ***P < 0.001, Student’s t test.
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of classical inhibitory NK receptors, by interacting with alternative 
ITIM-containing — but MHC-independent — Siglec receptors. Our 
present findings revealed that sialic acid–containing ligands of the 
human inhibitory NK cell receptors Siglec-7 and -9 were widely 
expressed on tumor cells of different histological origin. Expres-
sion of Siglec-7 and -9 ligands protected malignant cells from 
attack by NK cells in vitro and in an in vivo model, using mice 
with a reconstituted human NK cell compartment. Interference 
with Siglec-ligand interactions conferred substantially increased 
NK cell cytotoxicity, not only against NK cell–susceptible K562 
tumor cells, but also against NK cell–resistant cells. Depending on 
their differential expression on tumor cells, Siglec ligands might 
preferentially interact with the pan–NK cell receptor Siglec-7 or 
with Siglec-9, which was expressed on a mature subset of cytotox-
ic CD56dim NK cells with enhanced chemotactic potential. This 
CD56dimSiglec-9+ NK cell subset was found to be reduced in the 
peripheral blood of cancer patients.
The importance of directly studying the sialome on the intact 
cell or tissue, taking into account the spatial and complex cellu-
lar organization of sialic acid, has recently been highlighted (29). 
Therefore, we directly probed tumor cells and tissue sections for 
detection of Siglec ligands using recombinant soluble chimeras of 
Siglec molecules fused with the Fc portion of human IgG1. Such 
pseudoantibodies have been suggested to be powerful tools for 
detecting specific types and arrangements of sialic acids in situ 
(1). Given the broad Siglec-7 and -9 binding to different tumor 
types, it is conceivable that future pulldown assays using Siglec-Fc 
fusion proteins might lead to the identification of further physi-
ological or pathophysiological Siglec ligands and, importantly, of 
novel tumor markers and tumor-specific targets for therapy. Can-
didate ligands are tumor-related mucins that contain predomi-
nantly Ser- or Thr-linked (O-linked) oligosaccharides, including 
sialoconjugate tumor antigens (e.g., STN). Indeed, MUC16 has 
recently been identified as a ligand for Siglec-9 (20). Cell surface 
MUC16 is overexpressed by human epithelial ovarian tumors, 
and shed MUC16 can be detected in peritoneal fluid or serum as 
the tumor marker CA125. Other candidate ligands are ganglio-
sides, which are known to be highly expressed in a broad variety 
of tumor types (2) and have been reported to be specifically bound 
by Siglec-7 and -9 (38, 39). Notably, the gangliosides GD3, GD2, 
and GT1b are found predominantly on human tissue and tumor 
cells of neuroectodermal origin and constitute ligands for Siglec-7 
and -9, which in our analysis exhibited strong binding to mela-
noma cell lines or melanoma lesions in situ as well as to primary 
leukemic cells of patients with AML or CLL. Enhanced expression 
of the ganglioside GD3 in GD3 synthase–transfected P815 cells 
strongly bound to recombinant Siglec-7–Fc protein, but caused 
enhancement (rather than inhibition) of NK cell cytotoxicity, due 
Figure 5
CD56dimSiglec-9+ NK cells are less cytotoxic, yet exhibit features of enhanced chemotactic propensity. (A) Cytotoxic capacity of sorted 
CD56dimSiglec-9+ and CD56dimSiglec-9– NK cells against K562 cells (n = 7). (D) Migration of sorted CD56dimSiglec-9+ and CD56dimSiglec-9– NK 
cells to medium or medium supplemented with 1 nM rhIL-8 (n = 5). (B, C, E, and F) Flow cytometry for surface expression of inhibitory receptors 
(B and C) and of maturation, adhesion, and activation markers (E and F). Shown are frequency (C and F) and GMFI ratio of specific staining to 
isotype-matched control (B and E). *P < 0.05, ***P < 0.001, Student’s t test.
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to Siglec-7–independent effects (10). The ganglioside DSGb5 was 
reported to be expressed on renal carcinoma cells and to serve as a 
ligand for Siglec-7 (27). GD3 or DSGb5 expression alone had no 
effect on untreated NK cells, and pretreatment of NK cells with 
neuraminidase was required to inhibit NK cell cytotoxicity, proba-
bly by unmasking Siglec-7 (10, 27). In contrast to these reports, we 
showed here that unmodified expression of Siglec-7 or -9 ligands 
on malignant cells of distinct types of cancer was strong enough to 
directly inhibit antitumor responses of human primary NK cells. 
Hence, multiple heterogenous putative ligands for Siglec-7 and -9 
exist, and quantitative and qualitative differences in distinct 
tumor types appear to determine their protective capacity against 
NK cell–mediated immune responses.
To date, no detailed phenotypical analysis comparing 
CD56dimSiglec-9+ and CD56dimSiglec-9– NK cells has been per-
formed. Hence, the abundant expression of Siglec-9 ligands on 
tumor cells prompted us to phenotypically and functionally ana-
lyze this NK cell subset. We found that CD56dimSiglec-9+ NK cells 
exhibited a more mature phenotype, with higher expression levels 
of inhibitory KIRs and ILT2 receptors and concomitantly reduced 
— but still preserved — cytotoxic capacity to kill K562 target 
cells. In contrast, the chemotactic potential of CD56dimSiglec-9+ 
NK cells to migrate toward IL-8 was superior to that of 
CD56dimSiglec-9– NK cells, and surface expression levels of the che-
mokine receptors CXCR1 (IL-8 receptor) and CX3CR1 was higher 
on this subset. Based on telomere length, CD56dim NK cells had 
undergone approximately 5–10 more cell divisions than CD56bright 
NK cells, assuming an average telomere shortening of 50–100 bp 
per cell division (40). Interestingly, we found no difference in telo-
mere length between the CD56dimSiglec-9+ and CD56dimSiglec-9– 
NK cell subsets, despite the observed phenotypically fully mature 
state of peripheral blood CD56dimSiglec-9+ NK cells. These find-
ings are indicative of a proliferation-independent role of Siglec-9 
as a maturation marker. The frequency of CD56dimSiglec-9+ 
NK cells was higher in cord blood compared with adult periph-
eral blood, and neuraminidase treatment demonstrated that 
CD56dimSiglec-9+ NK cells comprised even the majority of cord 
blood CD56dim NK cells. These data suggest that acquisition of 
Siglec-9 is an early event upon differentiation from CD56bright to 
CD56dim NK cells, but expression of the receptor might be transient 
and only stabilized in cells that undergo full maturation, while 
being lost in activated short-lived NK cells. It has been proposed 
that immunological parameters in cancer could be used as a prog-
nostic factor (41). Indeed, immunological scores have been report-
ed as a better predictor of patient survival than contemporary his-
topathological methods used to stage colorectal cancer (42). In this 
regard, our observation that the frequency of CD56dimSiglec-9+ 
NK cells and Siglec-9 expression levels were reduced in the periph-
eral blood of malignant melanoma and CoACA patients warrants 
future clinical studies. Detailed analysis of patient samples at dif-
ferent stages of disease might test the suitability of Siglec-9 expres-
sion as a biomarker and provide explanations for the decreased 
occurrence of CD56dimSiglec-9+ NK cells in cancer.
Our findings indicate that targeting Siglec-7 and -9 on NK cells, 
or their ligands on malignant cells, might prove an attractive 
strategy by which to broaden indications or to implement current 
strategies for NK cell–based therapy to augment antitumor immu-
nity (43). The observation that NK cells were able to overcome the 
resistance of presumably NK cell–nonsusceptible tumor cells sug-
gests that this approach may expand the range of indications for 
NK cell–based strategies. Manipulation of inhibitory receptors has 
been recently exploited in the context of both innate (e.g., NK cells) 
and adaptive (e.g., CD8+ T cells) immunity to enhance antitumor 
activity. In both preclinical models and clinical trials of cancer 
patients, blockade of KIRs as well as interference with CTLA-4 or 
PD-1 provided solid in vivo evidence that modulation of the bal-
ance between inhibitory and activating signals in both adaptive and 
innate immune cells might represent an attractive strategy for com-
bating hematologic malignancies as well as solid tumors (43–47). 
Similarly, it might be speculated that the clinical efficacy of alloge-
neic KIR-mismatched human stem cell transplants in the clinical 
setting of leukemic diseases might be further enhanced by block-
ade of Siglec-7 and -9 on donor NK cells (48). Inversely, agonistic 
triggering of Siglec-7 and -9 as inhibitory NK cell receptors might 
prove promising in the context of reducing graft failure in certain 
types of solid organ transplantation (49). The cell type–restricted, 
Figure 6
The CD56dimSiglec-9+ NK cell subset is reduced in the peripheral blood of cancer patients. (A and B) Expression of Siglec-9 on peripheral blood 
NK cells of healthy donors (n = 22) or patients with melanoma (n = 11) or CoACA (n = 10). Shown are frequency (A) and GMFI ratio of specific 
staining to isotype-matched control (B), with or without neuraminidase treatment. Lines within boxes denote 50th percentile; upper and lower mar-
gins of the boxes denote 25th and 75th percentile; whiskers denote 5th and 95th percentile. *P < 0.05, **P < 0.005, ***P < 0.001, Student’s t test.
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differentiation-dependent expression pattern of Siglecs renders 
them attractive targets for functional targeting with agonists/
antagonists or in cell-based therapies (23, 50, 51). Siglecs, in par-
ticular Siglec-2, -3, and -8 (CD22, CD33, and Siglec-F, respectively, 
in the murine system) have been successfully targeted with differ-
ent approaches in preclinical models of autoimmune and allergic 
disorders, or, for the treatment of certain types of leukemia, in both 
preclinical and clinical trials (e.g., AML, non-Hodgkin lymphoma, 
and hairy cell leukemia) (23, 50). Our results provide insights into 
Siglec-7 and -9 receptor-ligand interactions in malignancy that may 
form the basis for novel therapeutic approaches and identification 
of novel diagnostic and prognostic biomarkers in human cancer.
Methods
Cells and tissues. Blood from healthy subjects was collected upon informed 
consent, or buffy coats were purchased from the Blood Transfusion Centres 
of Bern and Lausanne, Switzerland. Cord blood samples were obtained from 
umbilical cord veins immediately after delivery of the placenta (University 
Hospital of Lausanne, Lausanne, Switzerland, and University Hospital of 
Ghent, Ghent, Belgium). Peripheral blood was obtained from melanoma, 
CoACA, AML, and CLL patients. Archived tissue samples of melanoma, 
BCC, SCC, and CTCL between the years 2001 and 2006 from patients at the 
Department of Dermatology of Inselspital (Bern, Switzerland) were includ-
ed in this study. Mononuclear cells were obtained by density centrifugation 
using Ficoll-Hypaque solution (Biochrom AG). For functional experiments, 
NK cells were isolated using the NK cell negative selection kit from Stem-
Cell Technologies, according to the manufacturer’s instructions. Purity of 
isolated cells was always >95%, as assessed by CD56 and CD3 costaining. 
For experiments with NK cell subsets, cells were isolated using fluorescence-
activated cell sorting (FACS Aria, BD Biosciences). Cell lines were a gift from 
U. Zangemeister-Wittke (Institute of Pharmacology, University of Bern, 
Bern, Switzerland) and D. Stroka (Visceral and Transplantation Surgery, 
Department of Clinical Research, University of Bern, Bern, Switzerland).
mAbs and cell labeling. PBMCs, lymphocytes isolated from tissues or 
purified NK cells, were labeled using fluorescent mAbs directed against 
surface molecules (20 minutes at 4°C), washed in PBS with 0.2% BSA 
(Sigma-Aldrich), and acquired using a FACSCalibur or FACSVerse (BD Bio-
sciences). Cells were labeled either directly ex vivo or, where indicated, after 
30 minutes of treatment with 25 mU neuraminidase (Roche Diagnostics) 
at 37°C. Intracellular cytokine staining was done at 4°C for 30 minutes 
(see below). All mAbs were purchased from Biolegend, with the exception 
of anti-human Siglec-9, V450-conjugated anti-CD45, PerCP-conjugated 
anti-CD19, APC-conjugated anti-CD5, FITC-conjugated anti–IFN-γ, and 
PE-conjugated anti–MIP-1β (BD Biosciences); anti-human Siglec-7 (Beck-
man Coulter); anti-human NKG2A and NKG2C (R&D Systems); and 
eFluor 450–conjugated anti-human TNF-α (eBioscience). Anti-human 
KLRG1 mAb was a gift from H. Pircher (Universitätsklinikum Freiburg, 
Freiburg, Germany). Each mAb was titrated on PBMCs before use. Data 
analysis was performed using FCS Express. Fab fragments of unlabeled 
anti-human Siglec-7 and -9 mAbs were produced by papain digestion and 
subsequent purification using a protein A–Sepharose column Fab prepa-
ration kit (Pierce Biotechnology) according to the manufacturer’s instruc-
tions. Purity of the Fab fragments was confirmed by SDS-PAGE analysis.
Cell culture. All cell lines and purified human NK cells were cultured in 
RPMI medium (Sigma-Aldrich) supplemented with 10% FCS (Life Technolo-
gies) and complete medium (1% penicillin/streptomycin; Life Technologies). 
Cells were cultured for the indicated times in the presence of the cytokines 
rhIL-2 (100 U/ml; Proleukin, Roche Diagnostics), rhIL-8 (100 ng/ml; 
R&D Systems), rhIL-12 (50 ng/ml; Peprotech), rhIL-15 (50 ng/ml; Pepro-
tech), rhIL-18 (100 ng/ml; Peprotech), and rhIL-21 (20 ng/ml; Peprotech).
Telomere length measurement by automated multicolor flow-FISH. For telo-
mere length analysis, human NK cell subsets were isolated from the 
peripheral blood of 3 healthy donors by fluorescence-activated cell sorting 
as described above. Telomere length measurement by in situ hybridiza-
tion and flow cytometry (automated multicolor flow-FISH) was as previ-
ously described (52). Briefly, 5.3 × 104 to 1 × 106 cells were used for in situ 
hybridization. Cells were incubated with 170 μl hybridization mixture con-
taining 75% deionized formamide (Sigma-Aldrich), 20 mM Tris (pH 7.1; 
Sigma-Aldrich), and 1% BSA (Sigma-Aldrich) with no probe (unstained) or 
0.3 μg/ml telomere-specific FITC-conjugated (C3TA2)3 peptide nucleic acid 
(PNA) (Applied Biosystems). Denaturation was done at 87°C for 15 min-
utes, and hybridization was performed in the dark and at room temperature 
for 90 minutes. Excess and nonspecifically bound telomere PNA probe was 
removed by 4 wash steps at room temperature using 1 ml washing solu-
tion containing 75% formamide, 10 mM Tris, 0.1% BSA, and 0.1% Tween 
20 (Sigma-Aldrich), followed by 1 × 1 ml wash with a solution containing 
PBS, 0.1% BSA, and 0.1% Tween 20 at room temperature. DNA counter-
staining was performed using a solution containing PBS, 0.1% BSA, and 
a subsaturating amount of LDS 751 (0.01 μg/ml; Invitrogen) overnight. 
Acquisition of telomere fluorescence was performed using FACSCalibur 
(BD Biosciences). For each sample, unstained and telomere-stained samples 
were tested. FlowJo (Tree Star Inc.) was used for analysis of telomere length 
in the specific cell subsets. Specific telomere fluorescence was determined 
as the difference between the fluorescence of the stained samples minus 
the (auto-)fluorescence of the corresponding unstained sample. Using cali-
bration beads and an internal standard of cow thymocytes, the telomere 
fluorescence was calculated into kilobases of telomere length.
Chemotaxis assay. Standard Transwell chemotaxis assay was performed 
with subsets of human NK cells highly purified by fluorescence-activated 
cell sorting (FACS Aria; BD Biosciences). In brief, medium supplemented 
or not with 1 nM rhIL-8 (R&D Systems) was added to the lower cham-
ber of Transwell plates with 5-μM pores (Costar Corning). NK cells were 
added to the upper chamber, and plates were incubated for 3 hours at 
37°C. After incubation, equal volumes of CountBright bead (Invitrogen) 
solution were added to the migrated cells, and 3,500 beads were acquired 
per sample using a flow cytometer. The proportion of migrating cells was 
calculated by dividing the number of migrating cells by the total number 
and expressed as a percentage.
Proliferation assay. Purified NK cells were labeled with a final concentra-
tion of 5 μM CFSE (Molecular Probes), according to the manufacturer’s 
instructions. Cells were cultured in complete medium supplemented with 
rhIL-2 (400 U/ml; Roche Diagnostics) and rhIL-15 (50 ng/ml; Peprotech) 
in the presence of the indicated mAbs. CFSE fluorescence was evaluated at 
days 0, 6, and 9 on CD3–CD56+ cells by flow cytometry.
Survival assay. Purified NK cells were cultured in complete medium for 
24 hours in the presence of the indicated mAbs. Percentage of surviving 
cells was evaluated by propidium iodide (Sigma-Aldrich) and annexin V 
(BD Biosciences) staining, as previously described (33, 53), or by using 
GFP-conjugated recombinant annexin V (gift from T. Kaufmann, Univer-
sity of Bern, Bern, Switzerland).
Killing assay. Cytolytic NK cell activity toward susceptible target cell 
lines K562 and 721.221 and nonsusceptible HeLa cells was assessed 
using a standard 51Cr release assay. Briefly, purified NK cells were coin-
cubated at different E/T ratios with 51Cr-labeled cells, either untreated 
or neuraminidase treated, or in the presence or absence of Fab fragments 
or mAbs. After 4 hours, supernatants were collected, and 51Cr release 
was measured using a Top Count NXT microplate scintillator and lumi-
nescence counter (Packard BioScience). Specific lysis was calculated as 
(experimental – spontaneous release)/(total – spontaneous release) and 
expressed as a percentage.
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(Dako) and visualized with Liquid DAB+ Substrate Chromogen System 
(Dako). All tissue sections were counterstained with hematoxylin. For mor-
phologic analysis, an Axiovert 35 microscope (Carl Zeiss) was used.
Mice. NSG (NOD/LtSz-SCID IL-2Rγnull) mice were obtained from the 
Jackson Laboratory and maintained at the Institute of Experimental 
Immunology of University of Zurich under specific pathogen–free condi-
tions. Newborn NSG mice were irradiated with 100 cGy using a Cs source. 
5–6 hours after irradiation, mice were injected intrahepatically with 1 × 105 
CD34+ human hematopoietic progenitor cells derived from human fetal 
liver tissue (obtained from Advanced Bioscience Resources). Preparation 
of human fetal liver tissue and isolation of human CD34+ cells was done 
as described previously (32, 54). Reconstitution of human immune system 
components in mice (i.e., huNSG mice) was analyzed 10–12 weeks after 
engraftment and again before the start of experiments. Animals used in 
experiments were 4–5 month of age.
In vivo killing assay. K562 and HeLa target cells were labeled with 2 μM of 
the red fluorescent dye PKH26 (Sigma-Aldrich) according to the manufac-
turer’s protocol and extensively washed. Half of PKH26-labeled cells were 
then treated with 50 mU neuraminidase (Roche Diagnostics) in RPMI 
plus 0.5% FCS for 30 minutes at 37°C; the other half were left untreated. 
After incubation with neuraminidase, target cells were stained with 1 μM 
CFSE (Molecular Probes), whereas untreated cells were labeled with 5 μM 
CFSE. In each case, cell populations were washed, and 1–2 × 106 cells per 
population were injected i.p. into huNSG mice pretreated with 50 μg poly 
I:C (Invivogen) for 12 hours, as previously described (4). Cells were har-
vested after 12 hours by peritoneal lavage, pelleted, washed, and stained 
with antibodies against murine CD45 (Biolegend) and human NKp46 
(BD Biosciences) for 30 minutes on ice. Acquisition of flow cytometric 
data was performed on a LSR Fortessa cytometer (BD Biosciences).
Statistics. Unless otherwise indicated, data represent mean ± SEM. 
Significance of the results was determined using 2-tailed Student’s t test. A 
P values less than 0.05 was considered significant.
Study approval. All human studies were in accordance with the guidelines 
of — and approved by the cantonal ethical committees of — Bern, Lau-
sanne, and Zurich, Switzerland. Written informed consent was received 
from participants prior to inclusion in the study. All animal protocols 
were approved by the cantonal veterinary office of the canton of Zurich, 
Switzerland (protocol nos. 116/2008 and 148/2011).
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CD107a mobilization assay. For CD107a mobilization assay, purified 
human NK cells were incubated at a 1:1 ratio with target cell lines for 
4 hours, in the presence of CD107a mAb (Biolegend) and the indicated 
stimuli. After incubation, cells were washed with PBS plus 0.2% BSA 
(Sigma-Aldrich) and analyzed on a FACSVerse (BD Biosciences). Where 
indicated, target cells were pretreated with 25 mU neuraminidase (Roche 
Diagnostics) for 30 minutes (or for 1 hour, in the case of HeLa) at 37°C 
and washed extensively before coincubation.
Intracellular staining of cytokines. 105 resting NK cells were added to 105 
K562 cells in 200 μl complete medium. Target cells were treated with neur-
aminidase when needed. Cells were incubated for 1 hour at 37°C in 5% CO2. 
Thereafter, Brefeldin A (GolgiPlug; Becton Dickinson) was added to the 
cultures, which were incubated for 5 more hours. After a total of 6 hours 
of incubation, cells were spun down and incubated with fluorochrome-
conjugated mAbs for surface staining. Cells were then washed, fixed with 
2% paraformaldehyde in PBS, permeabilized, and stained intracellularly 
with fluorochrome-conjugated mAbs against cytokines and chemokines. 
Finally, cells were washed and analyzed on a BD FACSVerse (BD Biosci-
ences). Data were analyzed with FlowJo 10.0.6 software (Tree Star Inc.).
Cytokine secretion assay. Purified human NK cells were stimulated with 
rhIL-2 (Roche Diagnostics), rhIL-12 (Peprotech), and rhIL-18 (Peprotech) 
for 4 hours, in the absence or presence of mAbs. Supernatants were col-
lected and analyzed using the human Th1/Th2 CBA Kit, the Inflammatory 
Cytokine CBA Kit, and IFN-α and GM-CSF Flex Sets (BD Biosciences).
Quantification of Siglec-7 and -9 ligands on tumor cells and primary melano-
cytes. Tumor cell lines were maintained in complete medium or DMEM 
(Invitrogen) supplemented with 10% FCS and 1% penicillin/streptomycin. 
Primary melanocytes were maintained in Medium 154 (Invitrogen) supple-
mented with human melanocyte growth supplement (HMGS) (Invitrogen) 
and 1% penicillin/streptomycin. Peripheral blood SSCloCD45lo leukemia 
cells from AML patients and CD45+CD5+CD19+ cells from CLL patients 
were analyzed by flow cytometry. For Siglec ligand staining, recombinant 
human Siglec-hFcs (R&D Systems) were mixed with PE-conjugated anti-
human Ig (Jackson ImmunoResearch Laboratories) for 1 hour at 4°C before 
incubation with the cells for 30 minutes at 4°C. Where indicated, cells were 
pretreated with 25 mU neuraminidase (Roche Diagnostics) for 30 minutes 
at 37°C, or with 50 ng/ml rhTNF-α (R&D Systems) or 500 U/ml rhIFN-γ 
(gift from R. Dummer, Cancer Network Zurich, Zurich, Switzerland) for 
24 hours. Fluorescent staining was analyzed using FACSCalibur.
Quantification of Siglec-7 and -9 ligands on paraffin-embedded tissue sec-
tions. Siglec ligand expression on paraffin-embedded tissue sections 
(6 μm) was assessed by immunofluorescence microscopy and lectin 
immunohistochemistry. For immunofluorescence studies, recombinant 
human Siglec-hFcs (R&D Systems) were mixed with PE-conjugated anti-
human Ig (Jackson ImmunoResearch Laboratories) for 1 hour at 4°C 
before use. Melan-A was detected using anti-human Melan-A mAb (clone 
A103; Dako) and secondary anti-mouse Alexa Fluor 488–labeled antibody 
(Invitrogen, Molecular Probes). Tissue sections were analyzed by confocal 
laser scanning microscopy (LSM 510; Carl Zeiss)
For immunohistochemical analysis, paraffin-embedded tissue sections 
were deparaffinized with NeoClear and graded ethanol. Antigen retrieval 
was performed by heating the sections in DAKO target retrieval solution 
(Dako) for 3 minutes in a microwave, with intermediate cooling incubations 
of 30 minutes. Endogenous peroxidase activity was blocked with DAKO 
endogenous dual enzyme block (Dako), and specific staining of Siglec-7 
and -9 ligands was done with 5 and 3 μg/ml Siglec-hFcs (R&D Systems), 
respectively, for 90 minutes at 37°C, or with human IgG1 (Sigma-Aldrich) 
as negative control. A biotinylated goat anti-human (Fab)2 fragment (Jack-
son ImmunoResearch Laboratories) was used as secondary reagent. The 
complex was detected with streptavidin-conjugated horseradish peroxidase 
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